問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Others-

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

更新時間：2024-03-26

李重賓Li, Chung-Pin
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

Recruiting Trial

60Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李重賓

List

169Cases

2016-06-01 - 2019-05-31

Phase I

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors

  • Condition/Disease

    Advanced Tumors

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Terminated6Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

  • Condition/Disease

    Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

  • Test Drug

    avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙
Linkou Chang Gung Medical Foundation

白禮源
China Medical University Hospital-Taipei

未分科

2015-10-01 - 2017-02-15

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Condition/Disease

    unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated5Sites

Study ended1Sites

2013-03-31 - 2019-04-30

Phase III

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    Lenvatinib

Participate Sites
12Sites

Not yet recruiting12Sites

2013-09-01 - 2018-10-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-12-01 - 2014-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-08-01 - 2012-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-06-01 - 2017-12-31

Phase II

A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)- containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Metastatic Pancreatic Adenocarcinoma

  • Test Drug

    MM-398

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2016-12-01 - 2021-05-31

Phase I/II

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Treatment-Naïve (locally advanced) or Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

  • Condition/Disease

    Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

  • Test Drug

    Margetuximab

Participate Sites
3Sites

Terminated3Sites

趙毅
Taipei Veterans General Hospital

Digestive System Department

2015-07-01 - 2022-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Ramucirumab (Cyramza)

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

1 12 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB